Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNM NASDAQ:IMNN NASDAQ:KYNB NASDAQ:PLRZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$0.86-3.5%$1.03$0.86▼$1.86$26.98M-0.02144,143 shs113,153 shsIMNNImunon$1.51-9.0%$1.96$1.51▼$8.19$6.98M1.96225,717 shs91,576 shsKYNBKyntra Bio$7.03-0.6%$7.07$6.32▼$12.60$28.62M0.9612,301 shs2,691 shsPLRZPolyrizon$14.68-4.1%$13.54$2.88▼$18.20$31.91M-1.5938,981 shs117,798 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals-3.48%-6.71%-14.85%-32.81%-54.01%IMNNImunon-9.04%-17.49%-12.72%-45.88%-80.83%KYNBKyntra Bio-0.57%-2.77%+1.30%-1.54%+702,999,900.00%PLRZPolyrizon-4.11%+9.39%+22.95%-5.66%+30.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$0.86-3.5%$1.03$0.86▼$1.86$26.98M-0.02144,143 shs113,153 shsIMNNImunon$1.51-9.0%$1.96$1.51▼$8.19$6.98M1.96225,717 shs91,576 shsKYNBKyntra Bio$7.03-0.6%$7.07$6.32▼$12.60$28.62M0.9612,301 shs2,691 shsPLRZPolyrizon$14.68-4.1%$13.54$2.88▼$18.20$31.91M-1.5938,981 shs117,798 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals-3.48%-6.71%-14.85%-32.81%-54.01%IMNNImunon-9.04%-17.49%-12.72%-45.88%-80.83%KYNBKyntra Bio-0.57%-2.77%+1.30%-1.54%+702,999,900.00%PLRZPolyrizon-4.11%+9.39%+22.95%-5.66%+30.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 3.00Buy$5.00481.40% UpsideIMNNImunon 2.00Hold$10.00562.25% UpsideKYNBKyntra Bio 2.60Moderate Buy$32.50362.30% UpsidePLRZPolyrizon 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest IMNN, KYNB, ATNM, and PLRZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026IMNNImunon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/13/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/6/2026KYNBKyntra Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$35.006/26/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/16/2026KYNBKyntra Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)6/11/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/9/2026KYNBKyntra Bio Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.005/21/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/4/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium Pharmaceuticals$90K299.81N/AN/A$1.31 per share0.66IMNNImunonN/AN/AN/AN/A$2.30 per shareN/AKYNBKyntra Bio$6.44M4.42N/AN/A($4.20) per share-1.67PLRZPolyrizonN/AN/AN/AN/A$13.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$0.75N/AN/AN/AN/A-100.85%-47.89%N/AIMNNImunon-$14.49M-$5.16N/AN/AN/AN/A-341.23%-153.79%8/4/2026 (Estimated)KYNBKyntra Bio$183.45M$40.460.17N/AN/A2,199.13%N/A-36.71%N/APLRZPolyrizon-$3.34MN/AN/AN/AN/AN/AN/AN/AN/ALatest IMNN, KYNB, ATNM, and PLRZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026IMNNImunon-$0.87N/AN/AN/AN/AN/A5/12/2026Q1 2026IMNNImunon-$1.2150-$0.84+$0.3750-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/AIMNNImunonN/AN/AN/AN/AN/AKYNBKyntra BioN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25IMNNImunonN/A1.591.59KYNBKyntra BioN/A3.613.48PLRZPolyrizonN/A29.0329.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%IMNNImunon4.47%KYNBKyntra Bio72.71%PLRZPolyrizonN/AInsider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals0.60%IMNNImunon2.83%KYNBKyntra Bio4.15%PLRZPolyrizonN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.38 million29.32 millionOptionableIMNNImunon304.20 million4.08 millionNot OptionableKYNBKyntra Bio5704.05 million3.88 millionN/APLRZPolyrizonN/A2.08 millionN/AN/AIMNN, KYNB, ATNM, and PLRZ HeadlinesRecent News About These CompaniesPolyrizon (NASDAQ:PLRZ) Shares Up 1.7% - What's Next?July 22 at 2:20 AM | americanbankingnews.comPolyrizon Shareholders Approve New Executive Compensation Policy on July 13, 2026July 13, 2026 | tipranks.comPolyrizon Clears Key Safety Milestone for NASARIX Allergy Nasal SprayJuly 2, 2026 | tipranks.comPolyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ)July 2, 2026 | msn.comPolyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting ...July 2, 2026 | enidnews.comEPolyrizon Announces Successful Biocompatibility Results for NASARIX Allergy Blocker Nasal SprayJuly 2, 2026 | quiverquant.comQPolyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical TrialJuly 2, 2026 | globenewswire.comPolyrizon Wins Central IRB Nod for First NASARIX Allergy Blocker TrialJune 29, 2026 | tipranks.comPolyrizon Receives Central IRB Approval for First Human Clinical Trial of NASARIX Allergy BlockerJune 29, 2026 | quiverquant.comQPolyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical TrialJune 29, 2026 | globenewswire.comPolyrizon Announces U.S. Publication of Mucoadhesive Nasal Drug Delivery PatentJune 17, 2026 | tipranks.comPolyrizon Ltd.: Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery PlatformJune 17, 2026 | finanznachrichten.dePolyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery PlatformJune 17, 2026 | globenewswire.comPolyrizon Launches Key Human Study to Advance NASARIX Allergy Blocker Toward FDA PathwayJune 15, 2026 | tipranks.comPolyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory PathwayJune 15, 2026 | globenewswire.comPolyrizon Ltd.: Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery TechnologyJune 12, 2026 | finanznachrichten.dePolyrizon Marches on European PatentJune 11, 2026 | baystreet.caPolyrizon Wins European Patent Publication for Mucoadhesive Nasal Drug Delivery PlatformJune 10, 2026 | tipranks.comPolyrizon Ltd. Announces Publication of European Patent Application for Innovative Nasal Drug Delivery TechnologyJune 10, 2026 | quiverquant.comQPolyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery TechnologyJune 10, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMNN, KYNB, ATNM, and PLRZ Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$0.86 -0.03 (-3.48%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.86 0.00 (-0.47%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Imunon NASDAQ:IMNN$1.51 -0.15 (-9.04%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.55 +0.04 (+2.38%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.Kyntra Bio NASDAQ:KYNB$7.03 -0.04 (-0.57%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$7.01 -0.02 (-0.28%) As of 07/24/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Polyrizon NASDAQ:PLRZ$14.68 -0.63 (-4.11%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$14.86 +0.19 (+1.26%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Plugging In: How Kinder Morgan Powers Up Profits TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
